Syndax Pharmaceuticals Inc (Nasdaq: SNDX), a US-based clinical-stage biopharmaceutical company, announced on Monday that it has named Keith A. Goldan as its new chief financial officer, effective immediately.

With around thirty years of leadership and operational experience at various pharmaceutical, biotechnology and medical technology companies, Goldan has served as chief financial officer at Optinose, as well as chief financial officer of various private and public biopharmaceutical companies from early stage through commercial stage, including Optinose, Fibrocell, NuPathe, PuriCore plc, and Biosyn.

Goldan holds a BS in Finance from the Robert H. Smith School of Business at the University of Maryland and an MBA from the Wharton School at the University of Pennsylvania.